.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a typical follow-up of 11 months, people with metastatic gastrointestinal lumps that received biomarker-matched treatments based upon flowing cyst DNA profiling presented a more significant scientific advantage than those obtaining unmatched therapy.